Pathstone Holdings LLC Purchases 37,937 Shares of Sanofi (NASDAQ:SNY)

Pathstone Holdings LLC increased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 22.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 206,895 shares of the company's stock after acquiring an additional 37,937 shares during the quarter. Pathstone Holdings LLC's holdings in Sanofi were worth $9,981,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Sanofi during the 4th quarter worth approximately $135,933,000. Boston Partners lifted its position in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the period. Magnetar Financial LLC lifted its position in shares of Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the period. Finally, Regal Partners Ltd acquired a new position in shares of Sanofi during the 4th quarter valued at $35,034,000. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

NASDAQ SNY traded up $0.60 on Monday, reaching $52.28. 1,500,928 shares of the stock were exchanged, compared to its average volume of 2,377,379. Sanofi has a one year low of $45.80 and a one year high of $60.12. The firm has a market capitalization of $132.07 billion, a PE ratio of 21.00, a PEG ratio of 1.01 and a beta of 0.55. The company's 50-day simple moving average is $53.36 and its two-hundred day simple moving average is $51.88. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same period last year, the firm posted $1.78 EPS. The company's revenue was down 11.0% on a year-over-year basis. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is presently 57.14%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Finally, Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has an average rating of "Buy" and an average target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.